InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
2
T+90 hit rate
0%
T+90 mean return
-2.8%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Stengone Carmine N., Chief Executive Officer. Insider active across 2 companies, notably Contineum Therapeutics, Inc.. In total, 8 disclosures have been recorded. Breakdown: 1 buy · 2 sells. Total volume traded: €39k. History available since 11 September 2024. The latest transaction was filed on 8 July 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations8 total
2,500 shares@ US$1.01Class A Common StockSEC:0001628280-26-047710:0
2,500 shares@ US$16.00Class A Common StockSEC:0001628280-26-047710:1
7,500 sharesClass A Common StockSEC:0001628280-26-046653:0
2,500 sharesClass A Common StockSEC:0001628280-26-046653:1
10,000 sharesClass A Common StockSEC:0001628280-26-046653:2
4,400 shares@ US$1.260.0011% mcap50.0% of flowClass A Common StockSEC:0001437749-26-005892:0
4,400 shares@ US$1.2650.0% of flowClass A Common StockSEC:0001437749-26-005892
1,250 shares@ US$3.68100.0% of flowCommon StockSEC:0001372514-24-000115:0
Ideal exit: 8 Jun 2025 (T+270)
8 of 8 declarations
About Stengone Carmine N.
Carmine N. Stengone is the Chief Executive Officer of Contineum Therapeutics, Inc. He is responsible for the strategic and operational direction of the company. His expertise in the biotechnology sector is essential for the development of new therapeutic solutions.
